Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.

2.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

3.

Efficacy of human papillomavirus vaccines: a systematic quantitative review.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR.

Int J Gynecol Cancer. 2009 Oct;19(7):1166-76. doi: 10.1111/IGC.0b013e3181a3d100. Review.

PMID:
19823051
4.

HPV prophylactic vaccination: The first years and what to expect from now.

Villa LL.

Cancer Lett. 2011 Jun 28;305(2):106-12. doi: 10.1016/j.canlet.2010.12.002. Epub 2010 Dec 28. Review.

PMID:
21190794
5.

Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.

Villa LL.

Int J Infect Dis. 2007 Nov;11 Suppl 2:S17-25. doi: 10.1016/S1201-9712(07)60017-4. Review.

6.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Epub 2007 Jul 25. Review.

PMID:
17682997
8.

Human papillomavirus quadrivalent vaccine: a look behind the numbers.

Flaherty DK, Alkhateeb FM.

Ann Pharmacother. 2009 Apr;43(4):740-4. doi: 10.1345/aph.1L483. Epub 2009 Mar 10. Review.

PMID:
19276314
9.

Introducing human papillomavirus vaccines - questions remain.

Paavonen J, Lehtinen M.

Ann Med. 2008;40(3):162-6. doi: 10.1080/07853890701802404. Review.

PMID:
18382882
10.

[Diseases caused by human papilloma viruses].

Zollner U, Schwarz TF.

Dtsch Med Wochenschr. 2011 May;136(20):1067-72. doi: 10.1055/s-0031-1275845. Epub 2011 May 10. Review. German.

PMID:
21560109
11.

Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.

Paavonen J.

Int J Infect Dis. 2007 Nov;11 Suppl 2:S3-9. doi: 10.1016/S1201-9712(07)60015-0. Review.

12.

HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.

La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W.

Vaccine. 2007 Dec 5;25(50):8352-8. Epub 2007 Sep 29. Review.

PMID:
17996990
13.

Correlating immunity with protection for HPV infection.

Frazer I.

Int J Infect Dis. 2007 Nov;11 Suppl 2:S10-6. doi: 10.1016/S1201-9712(07)60016-2. Review.

14.

Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.

Society of Gynecologic Oncologists Education Resource Panel Writing group, Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, Wright J.

Gynecol Oncol. 2006 Sep;102(3):552-62. Review.

PMID:
16979432
15.

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.

Schwarz TF.

Adv Ther. 2009 Nov;26(11):983-98. doi: 10.1007/s12325-009-0079-5. Epub 2009 Dec 18. Review.

PMID:
20024678
16.
17.

Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia.

Pathirana D, Hillemanns P, Petry KU, Becker N, Brockmeyer NH, Erdmann R, Gissmann L, Grundhewer H, Ikenberg H, Kaufmann AM, Klusmann J, Kopp I, Pfister H, Rzany B, Schneede P, Schneider A, Smola S, Winter-Koch N, Wutzler P, Gross G.

Vaccine. 2009 Jul 23;27(34):4551-9. doi: 10.1016/j.vaccine.2009.03.086. Epub 2009 Apr 17. Review.

PMID:
19524337
18.

[Human papillomavirus prophylactic vaccines: stakes and perspectives].

Hantz S, Alain S, Denis F.

Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):647-55. Epub 2006 Jun 27. Review. French.

PMID:
16807045
19.

Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18.

Frederick PJ, Huh WK; PATRICIA Study Group.

Expert Rev Anticancer Ther. 2008 May;8(5):701-5. doi: 10.1586/14737140.8.5.701. Review. Erratum in: Expert Rev Anticancer Ther. 2008 Jun;8(6):1014.

PMID:
18471043
20.

Human papillomavirus infection and the primary and secondary prevention of cervical cancer.

Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M.

Cancer. 2008 Oct 1;113(7 Suppl):1980-93. doi: 10.1002/cncr.23704. Review.

Supplemental Content

Support Center